Blood-Based Circulating Microvesicles (cMV) Data to be Presented at the 2013 International Society for Extracellular Vesicles (ISEV)
Five Separate Research Presentations Offer Data on the Possible Future Application of Circulating Microvesicles to Cancer Care
IRVING, Texas, April 16, 2013 /PRNewswire/ — Caris Life Sciences(TM), a leading biosciences company focused on fulfilling the promise of personalized medicine, today announced that five data presentations related to blood-based circulating microvesicles (cMVs) will be presented this week at the 2013 International Society for Extracellular Vesicles (ISEV) meeting in Boston, Mass.
This research is part of the company’s development efforts for its Carisome® platform, which uses a novel, proprietary method to rapidly and accurately identify and characterize potential disease-associated circulating microvesicles found in the blood. This unique and promising technology platform has the potential for direct clinical utility in early diagnostic testing and disease and treatment monitoring in cancer patients.
“Caris Life Sciences is pioneering major advances in understanding and characterizing circulating microvesicles, as well as determining the ways in which their application to patient care could increase the accuracy of diagnosis and better guide therapeutic planning,” said Joachim Schorr, Ph.D., Chief Scientific Officer at Caris Life Sciences. “We believe our research efforts in this area hold tremendous potential across a broader array of diseases, including cancer, and represent a groundbreaking opportunity to fundamentally change the way medicine is practiced.”
ISEV will feature the following Caris Life Sciences poster presentations, along with one oral presentation:
Wednesday, April 17, 2013
- Abstract 135, Reference # 2279393: Daniel Holterman, Tassilo Hornung, Srividya Kankipati, et al. Identification and Implications of Transcription Factors in Circulating Microvesicles from Cancer Patients. Arlington-Berkley Room, Poster Session 1, 8:30 a.m.
- Abstract 129, Reference # 2279338: Tassilo Hornung, Srividya Kankipati, Candace Alva, et al. Effect of Colonoscopy on Circulating Microvesicles. Arlington-Berkley Room, Poster Session 1, 8:30 a.m.
- Abstract 130, Reference # 2279344: Jorge L. Schettini, Mukesh Maheshwari, Krunal Desai, et al., et al. Multi-Color Flow Cytometric Analysis of Cancer-Derived Microvesicles Reveals a Unique Subpopulation Ratio in Plasma from Prostate Cancer Patients. Arlington-Berkley Room, Poster Session 1, 8:30 a.m.
Friday, April 19, 2013
- Abstract 136, Reference # 2279403: Kirk M. Brown, Meredith P. Millis, Shannon E. Smith, et al. Circulating Microvesicles Contain Critical Elements of the RISC Complex. Statler Room, Poster VI RNA BIOMAR, 8:30 a.m.
Saturday, April 20, 2013
- Abstract 126, Reference # 2279325: David Spetzler. Differential Protein Expression and MiR Content of Sorted Subsets of Circulating Microvesicles from Cancer Patients and Healthy Controls. Imperial Ballroom, Session 31, 11:15 a.m.
As part of Caris’ presence at the 2013 ISEV meeting, a scientific symposium, Challenges and Opportunities in Advancing Solid and Blood-Based Tumor Profiling, is also planned for Wednesday, April 17, at 6 p.m. This symposium will feature presentations by the following Caris Life Sciences scientific experts:
- Joachim Schorr, Ph.D., Chief Scientific Officer – Opportunities in blood-based tumor profiling
- David Spetzler, Ph.D., MBA, MS, Vice President, Research and Development – Requirements for utilizing cMVs in the clinical standardization and stabilization of sample preparation
- Zoran Gatalica, M.D., DSc, Medical Director – Personalized molecular medicine today
About Caris Life Sciences
Caris Life Sciences is a leading biosciences company focused on fulfilling the promise of personalized medicine. Caris’ Molecular Intelligence(TM) Service (MI Profile(TM)) correlates molecular data generated from a patient’s tumor with biomarker/drug associations derived from the world’s leading clinical cancer literature. This service uses the most advanced and clinically-relevant technologies to provide physicians with information to aid in the selection of personalized cancer treatments more likely to work for each patient. Caris is also developing a series of blood tests based on the company’s proprietary Carisome® platform — a blood-based testing technology for diagnosis, prognosis, and theranosis of cancer and other complex diseases. Headquartered in the Dallas metroplex, Caris Life Sciences offers services throughout the United States, Europe, and other international markets. To learn more, please visit www.carislifesciences.com.
SOURCE Caris Life Sciences